SCHEMBL3758734

SCHEMBL3758734

NS(=O)(=O)c1ccc(-c2ccc(C(=C3C(=O)NNC3=O)c3ccccc3)o2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.47
GSK3B P49841 2/20 0.47
CA1 P00915 7/20 0.44
CA2 P00918 7/20 0.44
CA9 Q16790 5/20 0.44
CA12 O43570 3/20 0.44
CA14 Q9ULX7 2/20 0.44
MEN1 O00255 7/20 0.44
KMT2A Q03164 7/20 0.44
POLB P06746 4/20 0.43
G6PD P11413 1/20 0.43
GFER P55789 1/20 0.43
PTGS2 P35354 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
GAA P10253 1/20 0.41
AHR P35869 1/20 0.41
ALPL P05186 1/20 0.41
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5188402 0.88 CDK2 (0.48) CDK2GSK3BCA1CA2CA9
SCHEMBL5143187 0.87 CDK2 (0.47) CDK2GSK3BCA1CA2CA9
SCHEMBL5189038 0.87 CDK2 (0.48) CDK2GSK3BCA1CA2CA9
SCHEMBL5147453 0.71 KCNH2 (0.42) CDK2MEN1KMT2APOLBKDM4E
SCHEMBL5735124 0.70 ALDH1A1 (0.50) ALDH1A1GAAHPGD
SCHEMBL445807 0.70 CA2 (0.53) CDK2GSK3BCA1CA2CA9
SCHEMBL26054607 0.66 KDM4E (0.54) CDK2GSK3BCA1CA2CA9
SCHEMBL21067359 0.64 CDK2 (1.00) CDK2GSK3BMEN1KMT2APOLB
SCHEMBL18891690 0.62 ALDH1A1 (0.60) GSK3BCA1CA2CA9CA12
SCHEMBL308881 0.62 CA2 (1.00) CA1CA2CA9CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289569-A1 INHIBITORS OF UBIQUITIN E1 THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-11-15 US disclosed
US-8242160-B2 Inhibitors of ubiquitin E1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-08-14 US disclosed
US-20100305180-A1 INHIBITORS OF UBIQUITIN E1 WEISSMAN ALLAN M 2010-12-02 US disclosed
US-20080306130-A1 Inhibitors of ubiquitin E1 GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306130-A1 Inhibitors of ubiquitin E1 CUL1, UBQLN1, UBE2E1 CDK2 203/4885GSK3B 1606/4885CA1 3812/4885
US-20120289569-A1 INHIBITORS OF UBIQUITIN E1 CUL1, UBQLN1, UBE2E1 CDK2 203/4885GSK3B 1606/4885CA1 3812/4885
US-20100305180-A1 INHIBITORS OF UBIQUITIN E1 CUL1, UBQLN1, UBE2E1 CDK2 203/4885GSK3B 1606/4885CA1 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.